SI
PBYI icon

Sofinnova Investments’s Puma Biotechnology PBYI Stock Holding History

Sofinnova Investments’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-93,800
Closed -$3.64M – 81
2019
Q1 		$3.64M Buy
+93,800
New +$2.86M 0.35% 46

Other funds holding PBYI

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Sofinnova Investments's PBYI Position: Q2 2021 in Review

Sofinnova Investments sold out of Puma Biotechnology (PBYI) in Q2 2021, closing a stake of 344,917 shares — an estimated $3.35M sold.

Sofinnova Investments first reported a position in PBYI in Q2 2018 and held it in 8 quarters. The position peaked at $15.4M in Q3 2018. 120 funds tracked by Wall St. Rank hold PBYI as of Q2 2021.

  • Sofinnova Investments reported no remaining Puma Biotechnology position as of Q2 2021 after selling out during the quarter.
  • Sofinnova Investments sold 344,917 Puma Biotechnology shares in Q2 2021, an estimated $3.35M.
  • Sofinnova Investments first reported a position in Puma Biotechnology in Q2 2018 and held it in 8 quarters.
  • Sofinnova Investments's Puma Biotechnology position peaked at $15.4M in Q3 2018.
  • 120 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2021.

Based on Sofinnova Investments's 13F filing for Q2 2021, filed 16 Aug 2021.